FDA Approves ' Biosimilar ' Drug to Treat Certain Types of Anemia

TUESDAY, May 15, 2018 -- Retacrit (epoetin alfa-epbx) has been approved by the U.S. Food and Drug Administration as the first " biosimilar " to the anemia drugs Epogen and Procrit. Epogen and Procrit are approved to treat anemia caused by chronic...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news